Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-06-15
1997-07-08
Burn, Brian M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514825, 514863, 514909, A61K 31505
Patent
active
056461526
ABSTRACT:
Compounds of the formula ##STR1## wherein B, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are as defined herein with reference to formula IX have corticotropin-releasing factor antagonist activity and as such are of use in the treatment of panics, phobias and other stress-related disorders.
REFERENCES:
patent: 4229453 (1980-10-01), Roth et al.
patent: 4605642 (1986-08-01), Rivier et al.
patent: 4703049 (1987-10-01), Gillespie et al.
patent: 4885300 (1989-12-01), Press et al.
patent: 5063245 (1991-11-01), Abrev et al.
patent: 5464847 (1995-11-01), Courtemanche et al.
D. E. Grigoriadis et al., Peptides 10, 179-188 (1989).
E. B. DeSouza, J. Neuroscience 7(1), 88-100 (1987).
M. J. Owens et al., Pharm. Rev. 43(4), 425-473 (1991).
M. J. Owens et al, Pharm. Rev., 43, 425 (1991).
Bright Gene M.
Chen Yuhpyng L.
Welch Willard M.
Burn Brian M.
Ginsburg Paul H.
Pfizer Inc.
Richardson Peter C.
Zielinski Bryan C.
LandOfFree
Methods of administering CRF antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of administering CRF antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of administering CRF antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2409022